...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of pain & palliative care pharmacotherapy >Laxative Use in Inpatients on Oxycodone/Naloxone Prolonged Release and Oxycodone Prolonged Release for Cancer and Non-cancer Pain
【24h】

Laxative Use in Inpatients on Oxycodone/Naloxone Prolonged Release and Oxycodone Prolonged Release for Cancer and Non-cancer Pain

机译：在羟考酮/纳洛酮延长释放和羟考酮延长释放癌症和非癌症疼痛

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Our objective was to examine the laxative prescriptions in hospital inpatients with cancer and non-cancer pain on oxycodone compared to oxycodone plus naloxone combination. The study was designed as a retrospective case note review, and was conducted in a palliative care inpatient unit and a general medical ward in a large tertiary referral hospital. Eighty-four patients participated, receiving oxycodone or combination oxycodone/naloxone on general medical (45 patients) and palliative care wards (39 patients). The primary recorded outcomes were regular opioid dose (milligrams per day) and number of prescribed laxatives (type, doses, and frequency per day). Sixty-three (75%) patients in the study were on at least one laxative. In the general medicine inpatients, those on combined oxycodone/naloxone received on average 3.7 laxative doses per day compared to the oxycodone patients receiving 1.6 doses a day. In the palliative medicine population, both groups received a similar number of laxatives, despite the oxycodone/naloxone patients being on lower opioid doses. This retrospective study of hospital inpatients with cancer and non-cancer pain found that laxative use was not reduced in those on combined oxycodone/naloxone compared to oxycodone alone, suggesting that despite the interpretations of the clinical trials in the phase IV setting, the addition of naloxone had no effect on reducing laxative use.
机译：与羟考酮加上纳洛酮组合相比，我们的目的是检查羟考酮的癌症和非癌症疼痛的病院住院患者的泻药处方。该研究被设计为回顾性案例票据审查，并在姑息治疗的住院部门和大型高等教育医院中的一般医疗病房进行。八十四名患者参加，接受羟考酮或组合羟考酮/纳洛酮在一般医疗（45名患者）和姑息治疗病房（39名患者）。主要记录结果是常规的阿片类药物剂量（每天毫克）和规定的泻药数量（每天型，剂量和频率）。该研究中的六十三（75％）患者至少有一个泻药。在一般医学住院患者中，与羟考酮患者每天平均每天接受每天3.7剂量的羟考酮/纳洛酮组合的那些。在姑息的药物群体中，尽管羟考酮/纳洛酮患者在较低的阿片类药物上患者，但两组都接受了类似数量的泻药。这种回顾性研究患有癌症和非癌症疼痛的病院住院患者发现，与单独的羟考酮组合的羟考酮/纳洛酮组合使用泻药使用，表明尽管临床试验中的临床试验中的临床试验，请添加纳洛酮对减少泻药的使用没有影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号